Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Aeterna Zentaris Inc. and Lea...

NEW YORK, Jan. 8, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the Southern District of New York on behalf of those who purchased shares of Aeterna Zetaris Inc. ("Aeterna Zentaris" or the "Company") (NasdaqCM:AEZS) shares during the period between April 2, 2012 and November 6, 2014 (the "Class Period").

The Complaint charges Aetterna Zeratis and certain of its executives with violations of federal securities laws.  The complaint alleges during the Class Period defendants misrepresented or failed to disclose that: (1) the planned analysis of macimorelin's pivotal clinical trial failed to meet its primary efficacy endpoint pursuant to the Special Protocol Assessment agreement letter between the Company and the FDA; (2) insufficient data existed to confirm that the patients in the clinical trial were accurately diagnosed with Adult Growth Hormone Deficiency; (3) a serious cardiac event could have been attributed to macimorelin; (4) as a result, the FDA would not approve the New Drug Application for macimorelin in its present form; and (5), the Company's statements about its business, operations and prospects, including statements about macimorelin's prospects for FDA approval, were materially false and misleading and/or lacked a reasonable basis.

Plaintiff seeks to recover damages on behalf of all shareholders who purchased shares of Aeterna Zentaris during the Class Period described above.  

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint, to discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [e-mail]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.  If you suffered a loss in Aeterna Zentaris you have until January 12, 2015 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.  Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
[e-mail]

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-reminds-investors-of-class-action-against-aeterna-zentaris-inc-and-lead-plaintiff-deadline-of-january-12-2015-300017512.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Copyright 2015 PR Newswire